(BUSINESS WIRE)–Jan. 12, 2015– Lockheed Martin (NYSE:LMT) and Illumina, Inc. (NASDAQ:ILMN) today announced a new strategic alliance to collaborate on scalable and affordable genomics solutions to provide personalized health care for national populations. Genomics is the science of studying genomes or DNA. Applied to health care, analyzing a person’s DNA sequence data can provide a better understanding of health risks (such as how susceptible a person is to a particular disease or if the person may react to a type of medication), resulting in more precise and proactive medicine. By aggre… Read more
Shares of Illumina opened today at $195.92 and are currently trading down at $188.0405. ILMN has a 1-year high of $199.47 and a 1-year low of $113.15. The stock’s 50-day moving average is $187.99 and it’s 200-day moving average is $177.13.
On the ratings front, Illumina has been the subject of a number of recent research reports. In a report published on January 6, analyst Tycho Peterson from J.P. Morgan assigned a Buy rating to ILMN, with a price target of $270, which represents a potential upside of 37.8% from where the stock is currently trading. Separately, on November 28, Wedbush`s Zarak Khurshid maintained a Buy rating on Illumina shares and has a price target of $200.
In total,2 research analysts have assigned a Hold rating and 3 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $195.92 which is 3.4% above where the stock opened today.
Illumina, Inc., is developer, manufacturer and marketer of integrated systems for the large scale analysis of genetic variation and biological function.